Generic Test Developed for Early Detection of Cancer
|
By LabMedica International staff writers Posted on 07 Nov 2018 |
|
Image: The Pathfinder fully automated cell reader-analyzer system allows for optimized multimodal scanning, cell detection and analysis (Photo courtesy of IMSTAR).
Cancer is one of the leading causes of death worldwide. Early detection of cancer significantly raises the chances for an effective treatment. Cancer identification methods are mainly based on imaging, biopsies and a few nonspecific biomarkers.
There were about 18 million cancer cases diagnosed around the world in 2018. The number of new cancer cases per year is expected to reach more than 23 million by 2030. The most common cancers globally are lung cancer, breast cancer, and colorectal cancer.
Scientists at the University of Bradford (Bradford, UK) and their collaborators adapted the Lymphocyte Genome Sensitivity (LGS) technique, modified by a slightly different method and examined 700 more blood samples from 598 patients with cancer or suspected cancer and 102 healthy individuals. To help increase the sensitivity of the test and detect cancer at the level of each individual, they joined with the IMSTAR team (Paris, France) who analyzed the cells with their fully automated Pathfinder cell reader-analyzer system.
The new test, which is called TumorScan, is a highly sensitive test to detect any cancer at an early stage through the response of the white blood cells to UV treatment. These patient blood samples have also been collected at the stage before confirming diagnosis and treatment. There were four of these individuals with cancer who had received anti-cancer treatment. The results from these patients showed a reverse pattern compared to non-treated cancer patients and followed the pattern seen in healthy individuals.
The authors concluded that their study confirms that the modified method, TumorScan, which combines the adapted Comet assay with different UV treatments, designed and fully automated cell reader-analyzer, the IMSTAR Pathfinder, successfully improves the sensitivity of the original test (LGS test) for the detection of samples at the level of the individual. The study was published on October 12, 2018, in the journal FASEB BioAdvances.
Related Links:
University of Bradford
IMSTAR team
 RapiCardTM InstaTest (Serum-WB-Plasma).jpg)
There were about 18 million cancer cases diagnosed around the world in 2018. The number of new cancer cases per year is expected to reach more than 23 million by 2030. The most common cancers globally are lung cancer, breast cancer, and colorectal cancer.
Scientists at the University of Bradford (Bradford, UK) and their collaborators adapted the Lymphocyte Genome Sensitivity (LGS) technique, modified by a slightly different method and examined 700 more blood samples from 598 patients with cancer or suspected cancer and 102 healthy individuals. To help increase the sensitivity of the test and detect cancer at the level of each individual, they joined with the IMSTAR team (Paris, France) who analyzed the cells with their fully automated Pathfinder cell reader-analyzer system.
The new test, which is called TumorScan, is a highly sensitive test to detect any cancer at an early stage through the response of the white blood cells to UV treatment. These patient blood samples have also been collected at the stage before confirming diagnosis and treatment. There were four of these individuals with cancer who had received anti-cancer treatment. The results from these patients showed a reverse pattern compared to non-treated cancer patients and followed the pattern seen in healthy individuals.
The authors concluded that their study confirms that the modified method, TumorScan, which combines the adapted Comet assay with different UV treatments, designed and fully automated cell reader-analyzer, the IMSTAR Pathfinder, successfully improves the sensitivity of the original test (LGS test) for the detection of samples at the level of the individual. The study was published on October 12, 2018, in the journal FASEB BioAdvances.
Related Links:
University of Bradford
IMSTAR team
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
Latest Pathology News
- Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
- AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
- AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
- AI-Based Model Predicts Kidney Cancer Therapy Response
- Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
- World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
- Breakthrough Diagnostic Approach to Significantly Improve TB Detection
- Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read more
Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
